arrow
E

Elias B. Rashu

copenhagen university hospital - amager and hvidovre
H指数:8
被引数:210

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proteomic profiling of liver and plasma uncovers biomarkers and mechanisms in patients with primary biliary cholangitis

肝脏和血浆的蛋白质组学分析揭示了原发性胆汁性胆管炎患者中的生物标志物和机制

2026-10-010
OAAI
Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort

代谢功能障碍相关脂肪性肝病中非侵入性检查对纤维化诊断和事件预后的研究:一项前瞻性队列研究

2026-09-010
OAAI
Magnetic resonance imaging-derived extracellular volume fraction mapping in metabolic dysfunction-associated steatotic liver disease reveals subclinical cardiac remodelling

磁共振成像衍生的细胞外容积分数映射在代谢功能障碍相关脂肪性肝病中揭示亚临床心脏重塑

2026-04-280
OAAI
Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutide

代谢功能障碍相关脂肪性肝病中的一碳代谢改变可能被司美格鲁肽所修饰。

2025-08-300
OAAI
Circulating and hepatic levels of growth differentiation factor 15 in patients with metabolic dysfunction-associated steatotic liver disease
2024-12-040
PRE
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease

脂肪肝而不是2型糖尿病,体重指数或肝纤维化与脂肪变性肝病患者的高血糖素血症有关

2024-10-010
PRE
Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index
2024-07-081
OA
Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease

自身免疫性肝病患者的血糖紊乱与脂肪性肝病的机制不同

2024-06-012
PRE
Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD
2024-05-297
OAAI
Development and Evaluation of a Glucagon Sensitivity Test in Humans
2021-06-010
PRE